Alnylam Pharmaceuticals' Free Cash Flow rose 692.02% to $313.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.4 million, marking a year-over-year increase of 1278.10%. This contributed to the annual value of -$42.6 million for FY2024, which is 201.54% down from last year.
Per Alnylam Pharmaceuticals' latest filing, its Free Cash Flow stood at $313.0 million for Q3 2025, which was up 124.45% from $139.4 million recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Free Cash Flow ranged from a high of $342.3 million in Q3 2023 and a low of -$252.8 million during Q1 2021.
Moreover, its 3-year median value for Free Cash Flow was -$45.1 million (2023), whereas its average is $29.5 million.
Per our database at Business Quant, Alnylam Pharmaceuticals' Free Cash Flow tumbled by 130.04% in 2024 and then skyrocketed by 692.02% in 2025.
Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Free Cash Flow stood at -$172.0 million in 2021, then grew by 10.70% to -$153.6 million in 2022, then surged by 70.64% to -$45.1 million in 2023, then slumped by 130.04% to -$103.8 million in 2024, then surged by 692.02% to $313.0 million in 2025.
Its Free Cash Flow stands at $313.0 million for Q3 2025, versus $139.4 million for Q2 2025 and -$127.3 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value